Geode Capital Management LLC Purchases 45,566 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Geode Capital Management LLC increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,094,015 shares of the biotechnology company’s stock after buying an additional 45,566 shares during the period. Geode Capital Management LLC owned 2.45% of United Therapeutics worth $391,459,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. ClariVest Asset Management LLC lifted its stake in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares during the period. Innealta Capital LLC acquired a new position in shares of United Therapeutics during the 2nd quarter valued at $33,000. USA Financial Formulas bought a new position in United Therapeutics during the third quarter worth $33,000. Brooklyn Investment Group bought a new stake in United Therapeutics in the third quarter valued at $33,000. Finally, Capital Performance Advisors LLP bought a new position in shares of United Therapeutics during the 3rd quarter worth about $82,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other news, Director Christopher Causey sold 510 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total value of $192,081.30. Following the sale, the director now owns 3,675 shares of the company’s stock, valued at $1,384,115.25. The trade was a 12.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO James Edgemond sold 7,796 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $354.04, for a total transaction of $2,760,095.84. Following the completion of the transaction, the chief financial officer now directly owns 4,264 shares of the company’s stock, valued at approximately $1,509,626.56. This trade represents a 64.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 119,340 shares of company stock worth $44,765,530 over the last ninety days. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $361.81 on Friday. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82. The company’s 50-day moving average is $369.94 and its 200 day moving average is $341.68. The company has a market capitalization of $16.15 billion, a P/E ratio of 15.89, a price-to-earnings-growth ratio of 1.05 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same quarter last year, the business posted $5.38 EPS. United Therapeutics’s quarterly revenue was up 22.9% compared to the same quarter last year. As a group, research analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analyst Ratings Changes

UTHR has been the topic of several recent research reports. Jefferies Financial Group increased their price target on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Oppenheimer boosted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Argus raised their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH boosted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Finally, Wells Fargo & Company raised their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.